Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIG. 2.
FIG. 2.

Profiles of plasma glucose concentrations, ISR, plasma glucagon, and 3-OMG concentrations after a single injection of NN2211. Fasting and meal-related glucose was significantly reduced. The meal-related increment of ISR was increased, and the meal-related glucagon value was reduced. The profiles of insulin and C-peptide paralleled that of ISR. The insert in the bottom panel illustrates the delayed gastric emptying as measured by decreased AUC of 3-OMG. Data are mean ± SE.

This Article

  1. Diabetes vol. 51 no. 2 424-429